
Commentary|Podcasts|June 27, 2024
Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment
The PALOMA-3 trial showed subcutaneous amivantamab was better than IV among lung cancer patients.
Advertisement
This month, we spoke with Natasha B. Leighl, BSc, MMSc, MD, Medical Oncologist at the Princess Margaret Cancer Centre in Toronto, Canada. Leighl discussed the PALOMA-3 trial results, shared at the American Society of Clinical Oncology 2024 Conference. Leighl noted that the trial compared subcutaneous and intravenous administration of amivantamab for lung cancer.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
FDA Approves Imlunestrant Tablets for ER+, HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer
2
IMWG Consensus Risk Criteria Predicts Survival in Daratumumab Quadruplet Therapy
3
Linvoseltamab Monotherapy Elicits Promising ORR, MRD-Negativity in NDMM
4
How Pharmacists Support CDK4/6 Inhibitor Management and Patient Care
5